Frontier Biotechnologies Inc. (SHA:688221)

China · Delayed Price · Currency is CNY

27.73

+0.40 (1.46%)

At close: Jul 3, 2026

139.67% (1Y)

Market Cap	10.39B +180.4%
Revenue (ttm)	392.19M +194.5%
Net Income	3.46M
EPS	0.01
Shares Out	374.58M
PE Ratio	3,000.09
Forward PE	1,154.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,271,274
Open	27.50
Previous Close	27.33
Day's Range	26.55 - 28.12
52-Week Range	11.30 - 29.98
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Frontier Biotechnologies

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and me... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2002

Employees 314

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688221

Full Company Profile

Financial Performance

In 2025, Frontier Biotechnologies's revenue was 123.39 million, a decrease of -4.70% compared to the previous year's 129.47 million. Losses were -268.05 million, 33.1% more than in 2024.

Financial Statements